Keppra Side Effects: Headache
Headache is a common side effect of Keppra (levetiracetam), occurring in patients taking this antiepileptic medication, though it typically does not require discontinuation of therapy.
Overview of Headache as a Side Effect
According to the FDA drug label, headache is listed among the most common side effects of KEPPRA 1. The medication's official prescribing information identifies headache as one of the five most frequent adverse events reported in clinical trials 2.
Incidence and Clinical Significance
In controlled clinical trials:
- Headache was reported as one of the most commonly occurring adverse effects alongside somnolence, asthenia, dizziness, and infection 1
- The adverse event occurred in at least 1% of KEPPRA-treated patients and more frequently than in placebo-treated patients 1
- Research confirms headache as the second most common adverse effect after somnolence when analyzing the complete adverse effects profile 3
Clinical trials demonstrated that headache, along with asthenia and somnolence, appeared to occur predominantly during the first 4 weeks of treatment 1. This temporal pattern is clinically important for patient counseling and monitoring.
Dose-Related Considerations
The evidence shows:
- Headache occurred across all dose ranges studied (1,000 mg/day to 3,000 mg/day) 2
- In dose-response studies, headache was reported as a common adverse effect at both 1,000 mg/day and 2,000 mg/day doses 4, 5
- The frequency of headache did not show a clear dose-dependent relationship, unlike some other side effects such as somnolence 4
Management Approach
Patients should be informed that headache typically occurs early in treatment and often resolves without intervention 1. The FDA label advises patients to "tell your healthcare provider if you have any side effect that bothers you or that does not go away" 1.
Key Clinical Pitfalls:
- Do not automatically discontinue KEPPRA for headache alone, as it was not associated with high discontinuation rates in clinical trials
- Monitor for headache particularly during the first month of therapy
- Distinguish between medication-related headache and headache from underlying neurological conditions
- Consider that headache may be part of a broader adverse effect profile if accompanied by other neuropsychiatric symptoms
Context Within Overall Safety Profile
While headache is common, it is generally mild to moderate in intensity 1. More serious adverse effects requiring immediate attention include:
- Mood and behavior changes (aggression, depression, suicidal thoughts)
- Extreme sleepiness or weakness
- Problems with muscle coordination 1
The overall tolerability profile of levetiracetam remains favorable, with headache representing a manageable adverse effect that rarely necessitates treatment discontinuation 5.